Boston Children’s Hospital said Tuesday that it has partnered with Life Technologies Corp. to launch Claritas Genomics, a company whose mission is to develop next-generation, genetic and genomics-based diagnostic testing solutions.
Globe file photo of Sandra Fenwick. (Essdras M Suarez/ Globe Staff)
Claritas Genomics is majority-owned by Children’s Hospital.
‘‘While a number of academic and private ventures are offering genomic sequencing and molecular diagnostics to the public, no other partnership has integrated all the elements-fast, accurate genomic sequencing, bioinformatics, CLIA expertise, and access to researchers and clinicians who can interpret the data in a meaningful way,’’ Sandra Fenwick, president and chief operating officer of Boston Children’s, said in a statement. ‘‘We want to advance the standard of care, create a seamless experience, and extend it to children and adults across the US and around the world.’’
Boston Children’s Hospital today is a 395-bed comprehensive center for pediatric and
adolescent health care. It is also a teaching affiliate of Harvard Medical School.
Life Technologies is a global biotechnology company with 2011 sales of $3.7 billion.